ERBB2 and breast cancer: In mouse mammary tumor models, increased collagen levels, along with elevated β1 integrin and SRC activity, have been shown to contribute to combined resistance against HER2-targeted therapies (trastuzumab and pertuzumab) and anti-PI3K therapy (buparlisib) [116].